Back to Search
Start Over
Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridioides difficile infection in US hospitals.
- Source :
-
Antimicrobial resistance and infection control [Antimicrob Resist Infect Control] 2019 Jan 22; Vol. 8, pp. 17. Date of Electronic Publication: 2019 Jan 22 (Print Publication: 2019). - Publication Year :
- 2019
-
Abstract
- Backgound: Economic evaluations of interventions to prevent healthcare-associated infections in the United States rarely take the societal perspective and thus ignore the potential benefits of morbidity and mortality risk reductions. Using new Department of Health and Human Services guidelines for regulatory impact analysis, we developed a cost-benefit analyses of a national multifaceted, in-hospital Clostridioides difficile infection prevention program (including staffing an antibiotic stewardship program) that incorporated value of statistical life estimates to obtain economic values associated with morbidity and mortality risk reductions.<br />Methods: We used a net present value model to assess costs and benefits associated with antibiotic stewardship programs. Model inputs included treatment costs, intervention costs, healthcare-associated Clostridioides difficile infection cases, attributable deaths, and the value of statistical life which was used to estimate the economic value of morbidity and mortality risk reductions.<br />Results: From 2015 to 2020, total net benefits of the intervention to the healthcare system range from $300 million to $7.6 billion when values for morbidity and mortality risk reductions are ignored. Including these values, the net social benefits of the intervention range from $21 billion to $624 billion with the annualized net benefit of $25.5 billion under our most likely outcome scenario.<br />Conclusions: Incorporating the economic value of morbidity and mortality risk reductions in economic evaluations of healthcare-associated infections will significantly increase the benefits resulting from prevention.<br />Competing Interests: Not applicable.Has been obtained by all authors.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Subjects :
- Anti-Bacterial Agents therapeutic use
Clostridioides difficile drug effects
Clostridioides difficile physiology
Clostridium Infections microbiology
Clostridium Infections mortality
Cross Infection microbiology
Cross Infection mortality
Cross Infection prevention & control
Economics, Hospital
Humans
United States
Anti-Bacterial Agents economics
Antimicrobial Stewardship economics
Clostridium Infections economics
Clostridium Infections prevention & control
Cross Infection economics
Subjects
Details
- Language :
- English
- ISSN :
- 2047-2994
- Volume :
- 8
- Database :
- MEDLINE
- Journal :
- Antimicrobial resistance and infection control
- Publication Type :
- Academic Journal
- Accession number :
- 30680153
- Full Text :
- https://doi.org/10.1186/s13756-018-0459-1